Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting.
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors / E. Zattarin, D. Presti, L. Mariani, C. Sposetti, R. Leporati, A. Menichetti, C. Corti, C. Benvenuti, G. Fuca, R. Lobefaro, F. Ligorio, L. Provenzano, A. Vingiani, M. Del Vecchio, G. Griguolo, M. Sirico, O. Bernocchi, A. Marra, P. Zagami, E. Agostinetto, F. Jacobs, P. Di Mauro, A. Esposito, C.A. Giorgi, L. Lalli, L. Boldrini, P.P.B. Giacchetti, A.C. Schianca, V. Guarneri, R. Pedersini, A. Losurdo, A. Zambelli, D. Generali, C. Criscitiello, G. Curigliano, G. Pruneri, F. de Braud, M.V. Dieci, C. Vernieri. - In: NPJ BREAST CANCER. - ISSN 2374-4677. - 9:1(2023), pp. 27.1-27.5. [10.1038/s41523-023-00534-1]
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
C. Sposetti;R. Leporati;C. Corti
;F. Ligorio;L. Provenzano;A. Vingiani;M. Sirico;P. Zagami;L. Boldrini;A. Losurdo;C. Criscitiello;G. Curigliano;G. Pruneri;F. de Braud;
2023
Abstract
Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
